Up-to-date, above-mentioned 6 GLP-1 RAs have been approved for the treatment of patients with type 2 diabetes mellitus (T2DM), and all these drugs are administered by subcutaneous injection [33]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.